Prescient Therapeutics
We talked to Prescient Therapeutics‘ CEO Steve Yatomi-Clarke about the company’s PTX-100 programme, where a new drug is being developed for the treatment of T Cell Lymphoma. The Phase 1b data looks amazing, with a 40% Objective Response Rate and a 9 month Progression Free Survival average. Prescient Therapeutics believes as a new treatment option it can potentially gain FDA approval after a single Phase 2 study.
What are the Best ASX Stocks to invest in right now?
Check our ASX buy/sell tips
